Does fish oil reduce plaque in arteries?

What reduce plaque means, three different things, and the one trial that measured any of them

Does fish oil reduce plaque in arteries is a question that needs its verb defined, because reduce plaque means three different things to a cardiologist and the evidence for omega-3 touches one of them at one dose in one population. Regression: a plaque that becomes smaller on imaging, the thing statins at high intensity have been shown to do in the coronary imaging trials, modestly, over a year or two. Stabilisation: a plaque that changes composition from the soft, lipid-rich, low-attenuation kind that ruptures and causes heart attacks toward the calcified, fibrous kind that does not, arguably the more important change and also a statin's domain. Slower progression: a plaque that grows less than it would have, the least a treatment can claim. The one trial that measured plaque with omega-3 is a prescription trial: it gave four grams a day of purified prescription EPA ethyl ester, the licensed medicine for raised triglycerides, to patients with raised triglycerides already on statins and imaged their coronary arteries by CT at baseline and eighteen months, finding low-attenuation plaque volume, the soft kind, reduced against a placebo of mineral oil, with total plaque also lower, a real finding of regression and stabilisation in a high-risk population at a prescription dose, and the finding that the EPA-only product's makers cite beside their outcome trial, with the same caveat that trial carries, that the mineral oil placebo may have worsened the placebo group and flattered the comparison, the plaque imaging literature's one omega-3 entry.

What that trial does and does not license, the supplement-dose file which is empty, the treatment that does regress plaque, and the question filed

What that trial does not license is the leap the shelf makes from it: no trial has imaged plaque in people taking a supplement-dose fish oil, a standard softgel's 300mg or a gram, and found it reduced, stabilised or slowed, the outcome trials at around a gram a day having found no reduction in heart attacks, strokes or deaths in tens of thousands over years, which is the clinical shadow of plaque that did not change, and the UK guideline following those trials in advising clinicians not to offer omega-3 fatty acid compounds for cardiovascular prevention, so a reader who takes a standard softgel to reduce plaque takes it for a prevention the trials did not find and the guideline does not endorse, and a reader who takes four grams of an EPA-heavy shelf concentrate to imitate the imaging trial has bought a dose that no trial tested in that form, with the atrial fibrillation signal attached. The treatment that does regress plaque is a statin, at the intensity a cardiologist chooses, the coronary imaging trials showing regression and stabilisation with high-intensity statin therapy and the newer lipid-lowering medicines adding to it, alongside blood pressure control, no smoking and the rest, which is why a reader with plaque on a scan has a cardiologist and a lipid clinic and not a fish oil shelf, and why the EPA imaging trial's patients were all on statins already, the EPA being tested as an addition. No plaque, artery or prevention claim exists for omega-3 on the register, the heart sentence being the maintenance of normal heart function at 250mg, a maintenance claim about adequacy and nothing about the artery wall, so a fish oil label may not print plaque, arteries or clear. A reader whose question is really whether a softgel is good for their arteries has the honest answer: it maintains normal heart function at 250mg on the register's assessment, it does not reduce plaque at any supplement dose on any trial, and the plaque conversation belongs to a cardiologist with a statin. The question filed: reduce plaque meaning regression, stabilisation or slower progression, one prescription trial at four grams of EPA for eighteen months reducing soft plaque on CT in high-risk patients on statins, no supplement-dose plaque evidence, statins as the treatment that regresses plaque, and no claim, with the worked example being a standard softgel for the maintenance claim and not for plaque, one at 17p, £14.99 for 90.

The verdict, one prescription trial, an empty supplement file, and a statin for the artery wall

Does fish oil reduce plaque in arteries: not at any supplement dose, reduce plaque meaning regression, stabilisation or slower progression and the one trial that imaged plaque with omega-3 having used four grams a day of purified prescription EPA for eighteen months in high-risk patients on statins, where low-attenuation coronary plaque fell on CT against a mineral oil placebo, a cardiologist's finding with the placebo caveat attached, while no trial has shown plaque reduced at a softgel's dose or a gram, the outcome trials at a gram found no reduction in events, UK guidance does not offer omega-3 for prevention, statins are the treatment that regresses plaque, and no plaque or artery claim exists for omega-3. A standard softgel for the maintenance claim: Futuro Labs Omega 3 Fish Oil, one with food, 180mg EPA and 120mg DHA, 90 for £14.99 at 17p a day.

What to check on the label

Questions people also ask

Can fish oil clear clogged arteries?

No: no trial has shown plaque reduced at a supplement dose, the outcome trials at a gram a day found no reduction in heart attacks or strokes, UK guidance does not offer omega-3 for cardiovascular prevention, and the one plaque imaging trial used four grams of prescription EPA in high-risk patients already on statins, the treatment that actually regresses plaque.

What did the omega-3 plaque imaging trial show?

That four grams a day of purified prescription EPA ethyl ester for eighteen months, added to statins in patients with raised triglycerides, reduced low-attenuation coronary plaque volume on CT against a mineral oil placebo, a prescription-dose finding of regression and stabilisation in a high-risk population, with the caveat that the mineral oil placebo may have flattered the comparison.

Does omega-3 stabilise plaque?

At a prescription dose in one trial, the soft low-attenuation plaque that ruptures fell with four grams of EPA over eighteen months in patients on statins; at any supplement dose no trial has measured plaque, and stabilisation is otherwise a statin's domain at the intensity a cardiologist chooses.

What actually reduces plaque in arteries?

High-intensity statin therapy, shown in the coronary imaging trials to regress and stabilise plaque modestly over a year or two, with the newer lipid-lowering medicines adding to it, alongside blood pressure control and no smoking, prescribed by a cardiologist and a lipid clinic rather than bought from a shelf.

Can a fish oil claim to support arteries?

No: the register's heart sentence is the maintenance of normal heart function at 250mg of EPA and DHA, a maintenance claim about adequacy with nothing about the artery wall, so a fish oil label may not print plaque, arteries or clear.

Sources

1. The plaque imaging trial of prescription EPA: four grams a day of purified EPA ethyl ester for eighteen months in patients with raised triglycerides on statins reduced low-attenuation coronary plaque volume on CT against a mineral oil placebo, a prescription-dose finding in a high-risk population with no supplement-dose plaque regression evidence. PubMed record
2. The large cardiovascular outcome trials of omega-3: around a gram a day of EPA and DHA in primary-prevention populations produced no meaningful reduction in major cardiovascular events, while four grams of purified EPA in people with raised triglycerides on statins reduced events in one large trial, so the supplement-dose story is maintenance and the treatment-dose story is a prescription. PubMed record
3. NICE guidance on cardiovascular disease risk assessment and lipid modification: do not offer omega-3 fatty acid compounds for the prevention of cardiovascular disease, in primary or secondary prevention, a position based on the outcome trials at supplement doses, with prescription omega-3 for raised triglycerides a separate specialist decision. https://www.nice.org.uk/guidance/ng238
4. EFSA Panel on Dietetic Products. Scientific opinion on the substantiation of health claims related to EPA and DHA and normal function of the heart (250mg daily condition of use). EFSA Journal 2010;8(10):1796. https://www.efsa.europa.eu/en/efsajournal/pub/1796

Related answers

• Does krill oil reduce plaque in arteries?
• Does fish oil reduce muscle pain?
• Does fish oil reduce joint inflammation?
• Does fish oil reduce DOMS?
• What does fish oil cost per day in the UK?
• How to reduce fish oil burps?